Interleukin gene polymorphisms in pneumoconiosis

  • Authors:
    • Simone Helmig
    • Martin Grossmann
    • Jelena Wübbeling
    • Joachim Schneider
  • View Affiliations

  • Published online on: May 10, 2012     https://doi.org/10.3892/ijmm.2012.996
  • Pages: 401-408
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Inhaled asbestos fibres are known to cause inflammation processes with the result of lung or pleural fibrosis and malignancies. Interleukins (IL), such as IL-1β, IL-6 and IL-10, have various functions in the regulation of the inflammatory response and in proliferative processes after inhalation of silica dust and can, therefore, influence the pathogenesis of asbestos-induced fibrosis and carcinogenesis. Polymorphisms within these genes may be associated with susceptibility to silica and asbestos-induced lung diseases. Thus, IL-1β, IL-6 and IL-10 polymorphisms were examined to determine an association with asbestos or silica-induced fibrosis or malignancies. Association studies were performed in 1180 individuals, using control subjects (n=177), fibrosis patients (n=605), lung cancer (LC) patients (n=364) and malignant mesothelioma (MM) patients (n=34). IL-1β (C-511T; C+3954T), IL-6 (G-174C) as well as IL-10 (G-1082A) polymorphisms were investigated. Compared to a healthy (control) group, a higher risk was seen for malignant mesothelioma patients in all investigated polymorphisms. The IL-6 -174C allele showed a tendency towards a higher risk for fibrosis or asbestos-induced lung cancer (ORasbestosis, 1.338; 95% CI, 0.71-2.53; ORsilicosis, 1.226; 95% CI, 0.54-2.81; ORfibrosis other aetiology, 1.313; 95% CI, 0.58-2.98 and ORLC asbestos, 2.112; 95% CI, 0.75-5.92). The IL-10 -1082A carrier seemed to be at higher risk for silicosis (ORsilicosis, 2.064; 95% CI, 0.78-5.49) but not for asbestosis. In summary, this study did not reveal sufficient evidence for a significant association of the investigated interleukin polymorphisms with asbestos or silica-induced diseases in the population studied.

Introduction

Inhaled asbestos fibres are known to cause progressive lung or pleural fibrosis and malignancies, such as lung cancer or diffuse malignant mesothelioma (1). Interindividual differences might play a crucial role in the outcome and severity of asbestos diseases (2). Inflammatory processes are of general importance in the pathogenesis of asbestosis and also in silicosis, as they are driven by chronic inflammation due to inhaled fibres and particles (3). The inhalation of asbestos or silica leads to interleukin-1β (IL-1β) secretion, which plays a key role in the pathogenesis of occupational-related pneumoconiosis (4,5). IL-1β is a pro-inflammatory cytokine with wide ranging effects on gene expression, such as upregulating cytokines and tissue remodelling enzymes (6,7). Chronic overexpression of IL-1β may also contribute to the growth, vascularisation and metastasis of malignant tumours (810).

The IL-6 multifunctional cytokine has the potential of initiating a fibrogenic response after asbestos exposure (11). As a result of the fibres, lung epithelial cells release IL-6, which in turn stimulates lung fibroblast DNA synthesis (12). Several studies have reported an involvement of IL-6 in the pathogenesis of inflammatory diseases such as coal workers’ pneumoconiosis (CWP) (13) rheumatoid arthritis (14), chronic arthritis (15) and psoriasis (16).

Single-nucleotide polymorphisms (SNPs) in regulatory regions of cytokine genes have been associated with susceptibility to a number of complex disorders (1719). The T alleles of the IL-1β C+3954T (rs1143634) and C-511T (rs16944) polymorphisms have been shown to correlate with higher IL-1β-protein levels in vitro (20,21). On the other hand, the C allele of the IL-6 G-174C polymorphism (rs1800795) was found to be associated with significant lower levels of plasma IL-6 (22).

IL-10 is an important immunosuppressor cytokine, controlling the balance between inflammatory and humoral response by inhibiting the release of pro-inflammatory mediators such as IL-1β and IL-6. Physiologically it is produced after pro-inflammatory mediators and, therefore, plays a role in limiting an excessive immune response and collateral damage (23,24). Interindividual variations of IL-10 levels (mRNA and serum protein levels) are genetically controlled by polymorphic variants present at the gene promoter. The G allele at position −1082 seems to be the most important genetic factor in the regulation of IL-10 levels (25).

In the present study, we investigated the distribution of genotype frequencies of proinflammatory mediator polymorphisms (IL-1β C+3954T, IL-1β C-511T and IL-6 G-174C) and the anti-inflammatory cytokine IL-10 polymorphism (IL-10 G-1082A) in patients with asbestos- or silica-induced fibrosis or malignancies.

Materials and methods

Subjects

The study population consisted of a total of 1180 German individuals. All subjects included in this study were interviewed using a questionnaire to obtain information on lifestyle (including a lifetime history of tobacco use) and occupational history. According to their reported smoking habits, patients were classified into smokers, ex-smokers or never smokers. Individual smoking pack years (PY) were calculated. One PY was defined as smoking 20 cigarettes daily over one year. Written informed consent was obtained from all patients before inclusion in the study.

The control group comprised of 177 unrelated, healthy subjects without known diseases and without any exposure to carcinogenic (or fibrogenic) agents at the work place. Any subject with diseases related to potential tissue fibrosis (e.g. diabetes, chronic lung disease) or with benign or malignant tumors were excluded.

The lung fibrosis patients group contained 605 subjects. Only subjects with confirmed diagnosis of lung fibrosis, according to the WHO criteria (26,27) were included. The lung cancer patient group contained 364 and the malignant mesothelioma group contained 34 patients. Only subjects with histological confirmed diagnosis of primary lung cancer or diffuse malignant mesothelioma, according to the WHO criteria (28), were included.

Diagnosis of pulmonary diseases was based on physical examination, haematological, biochemical and immunological laboratory analyses and pulmonary function tests. All patients underwent diagnostic procedures, including X-ray examination interpreted according to the International Labour Office (ILO) Classification of Radiographs of Pneumoconiosis (29).

To allow further discrimination between different kinds of exposure, several groups of patients suffering from fibrosis or lung cancer were created and compared to a non-exposed control group (Table I). In a second evaluation step, the asbestosis group was further subdivided into groups considering the expansion and severity code of fibrosis. These groups were established using chest X-ray findings according to the ILO Classification of Radiographs of Pneumoconiosis (29).

Table I

Discrimination between different kinds of exposure.

Table I

Discrimination between different kinds of exposure.

DiseasesNDefinitionDiagnosis criteria (Ref.)
Asbestosis389BKV 4103 according to the German list of occupational diseasesCaused by asbestos dust; diagnosis criteria (48)
Silicosis161BKV 4101 according to the German list of occupational diseasesCaused by silica dust; diagnosis criteria (29)
Lung interstitial fibrosis55No relevant exposure to asbestos
Asbetos-related lung cancer49BKV 4105 according to the German list of occupational diseasesDiagnosis criteria (49)
Diffuse malignant mesothelioma34BKV 4105 according to the German list of occupational diseasesCaused by asbestos dust
Lung cancer315No relevant exposure to asbestos

[i] Several groups of patients suffering from lung fibrosis or lung cancer were created and compared to a non-exposed control group. BKV, German classification system of occupational diseases.

Chest X-ray findings

Chest X-rays were reviewed and graded according to the ILO 2000 classification. According to the ILO standard X-rays, three profusions (1, 2 and 3) and the six size and shapes of the opacities (p, q, r for rounded, s, t, u for irregular, and A, B and C for large opacities) were coded. Asbestos-related abnormalities were classified as asbestosis (parenchymal changes) or as asbestos-induced pleural diseases (Table II) (29). Diffuse pleural thickening without parenchymal bands were only observed in adipose patients and as such were attributed to subpleural fat. The Ethics Committee of the University Hospital, Giessen, Germany, approved the study (AZ:75/06).

Table II

X-ray classification of asbestosis and pleural plaques.

Table II

X-ray classification of asbestosis and pleural plaques.

GradeClassification group
Classification of parenchymal changes
  <1/0No definite lung fibrosis
  1/1 and 1/2Beginning lung fibrosis
  2/1, 2/2 and 2/3Moderate lung fibrosis
  3/2, 3/3 and 3/+Severe lung fibrosis
Classification of pleural changes
  0No definite pleural plaques
  1< 1/4 of lateral thoracic wall
  21/4–1/2 of lateral thoracic wall
  3>1/2 of lateral thoracic wall
  Hyalinosis complicataCostophrenic obliteration; diffuse pleural thickening; pleuro-parenchymal fibrous strand (‘crow feet’)

[i] The groups were established using chest X-ray findings according to the International Labour Office Classification of Radiograhs of Pneumoconiosis (29).

Real-time PCR and polymorphism detection

Whole blood (3 ml) samples were collected by venipuncture in tubes containing EDTA (Sarstaedt, Nümbrecht, Germany). Genomic DNA was isolated from whole blood using the Versagene™ DNA purification kit (Gentra Systems, Minneapolis, MN, USA). Detection of the polymorphisms was performed by rapid capillary PCR, with melting curve analysis, using fluorescence-labelled hybridisation probes in a LightCycler System (Roche Diagnostics, Mannheim, Germany). The PCR primers as well as the fluorescent-labelled detection probes were synthesized by TIB Molbiol (Berlin, Germany) (Table III). The reaction mixture (20 μl) for IL-1β C+3954T comprised 2 μl of forward primer (10 μM), 1 μl of reverse primer (10 μM) and 0.4 μl of each probe (10 μM), 1.2 μl MgCl2 (25 mM), 2 μl FastStart DNA Master Hybridization Probes (Roche Diagnostics) and 2 μl DNA. The reaction mixture (20 μl) for IL-6 and IL-10 comprised 0.6 μl of each primer (10 μM) and 0.4 μl of each probe (10 μM), 10 μl ABgene QPCR Capillary Master Mix (Thermo Fisher, Dreieich, Germany) and 2μl DNA. Annealing temperatures were 60°C for IL-1β C+3954T, 57°C for IL-6 G-174C and 63°C for IL-10 G-1082A polymorphism. The melting curves were generated to obtain melting temperatures. PCR contamination was checked by the inclusion of negative control, where cDNA was replaced by water.

Table III

Primer and probe sequences for interleukin polymorphisms.

Table III

Primer and probe sequences for interleukin polymorphisms.

GeneSNPPrimerPrimer sequence 5′→3′
IL-1β+3954 (C→T)Forward 5′-CCTGCCCTTCTGATTTTATACC-3′
Reverse 5′-CAGGATGTTTCCATTTACCTTG-3′
Anchor TCGTGCACATAAGCCCTCGTTATCCC-FL
+3954(T) 640-TGTGTCAAAGAAGATAGGTTCTGAAA-p
−511 (C→T)Forward 5′-TGGCATTGATCTGGTTCATC-3′
Reverse 5′-GTTTAGGAATCTTCCCACTT-3′
EnzymeAval
IL-6−174 (G→C)Forward 5′-TTACTCTTTGTCAAGACATGCCA-3′
Reverse 5′-ATGAGCCTCAGACATCTCCAG-3′
Anchor AGCTGCACTTTTCCCCCTAGT-F1
−174(G) 640-GTGTCTTGCGATGCTAAAGGA-p
IL-10−1082 (G→A)Forward 5′-CTCGCTGCAACCCAACTGGC-3′
Reverse 5′-ATGGGGTGGAAGAAGTTGAA-3′
Anchor GGATAGGAGGTCCCTTACTTTCCTCTTACC-F1
+3954(G) 640-CCCTACTTCCCCCTCCCAAA-p

Detection of the IL-1β C-511T polymorphisms was performed by restriction fragment length analysis (RFLA). The reaction mixture (22 μl) for the PCR consisted of 1 μl of each primer (TIB Molbiol) (Table III), 1 μl Q-solution, 2 μl 10X buffer, 2 μl MgCl2, 1 μl HotstarTaq® Plus (all from Qiagen, Hilden, Germany) 0.2 μl dNTPs (Fermentas, St. Leon-Rot, Germany) and 2 μl DNA. Annealing temperatures in 40 cycles was 58°C. As a restriction enzyme AvaI (New England Biolabs, Ipswich, MA, USA) was used. Results were visualised by agarose gel electrophoresis.

Statistical analysis

The odds ratios (OR) and confidence intervals (CI) assessed the association between genotype distribution and patient status. The OR and 95% CI were used as an estimate of the risk in all cases and were calculated by unconditional logistic regression. Adjustments for age, gender and tobacco smoking (PY) were computed to estimate the association between certain genotypes and diseases. Current smokers at the time of diagnosis were considered smokers. Ex-smokers were all the people who had ever smoked. Information was collected on the usual number of cigarettes smoked per day, the age at which the subject started smoking and, if the person was an ex-smoker, the age at which the subject stopped smoking. PY were calculated for the cumulative cigarette smoking. The smokers were stratified by the PY values. All statistical analyses were performed using the statistical software package, SSPS 17.0 (SPSS Inc., Chicago, IL, USA). Allelic and genotype frequencies were obtained by direct counting. The Hardy-Weinberg equilibrium was assessed by a χ2 test with 2 degrees of freedom. Allelic and genotype frequencies in patient and control groups were compared using a 2×2, contingency table and a χ2 test or the 2-tailed Fisher’s exact test when the number of expected cases was too low. The level of significance was set at P<0.06.

Results

More smokers or ex-smokers were present in the patient (81%) compared to the control (42%) group. The lung cancer patient group (91%) but not the malignant mesothelioma group (42%) included more smokers when compared to the controls (Table IV). The mean age of the control group was 39.2 years (range 20–76) and 67.5 years (range 29–91) for all the cases.

Table IV

Demographic and disease parameters of controls and patients.

Table IV

Demographic and disease parameters of controls and patients.

nAge (years)
Smoking habit (%)
MeanRangeMedian Smoker/ex-smoker
Control total17739.1920.0–75.534.958.2
Patient total100367.4629.2–91.268.881
Lung fibrosis60568.1829.2–91.269.377
  Silicosis (BKV 4101)16170.4740.3–88.971.580.7
  Asbestosis (BKV 4103)38967.8945.7–91.268.677.1
  Lung fibrosis of other aetiology5563.529.2–82.163.865.5
Malignant mesothelioma (BKV 4105)3466.634.3–83.968.244.1
Lung cancer36466.634.3–83.968.290.9
  Asbestos induced lung cancer (BKV 4104)4966.950.4–80.967.498
  Lung cancer of other aetiology31566.534.3–83.968.389.8
Clinical manifestation of IL-6 G-174C polymorphisms

The frequency of the IL-6 (−174) C allele in the control group as well as in the patients group was 0.45. OR analyses were performed for the genotype G-174G vs. the genotypes carrying at least one C allele (G-174C or C-174C). Data was adjusted for PY, age (years) and gender.

This analysis revealed that patients carrying at least one C allele of the IL-6 −174 polymorphism were at higher risk for fibrotic lung diseases (ORasbestosis, 1.338; 95% CI, 0.71–2.53; ORsilicosis, 1.226; 95% CI, 0.54–2.81 and ORfibrosis other aetiology, 1.313; 95% CI, 0.58–2.98). Additionally higher risk were revealed for malignant mesothelioma (ORMM, 1.918; 95% CI, 0.68–5.45) and asbestos-induced lung cancer (ORLC asbestos, 2.112; 95% CI, 0.75–5.92) but not for lung cancer of other aetiology (ORLC other aetiology, 1.00; 95% CI, 0.52–1.93) (Table V).

Table V

Adjusted odds ratio of IL-6 G-174C polymorphisms.

Table V

Adjusted odds ratio of IL-6 G-174C polymorphisms.

Genotype, n (%)
Multivariate analysis
DiagnosisnGGGC or CCOR95% CIp-value
Lung fibrosis605213(35.2)392 (64.8)1.3070.725–2.3560.373
  Silicosis (BKV 4101)16156 (34.8)105 (65.2)1.2260.535–2.8090.63
  Asbestosis (BKV 4103)389138 (35.5)251 (64.5)1.3380.708–2.5320.37
  Lung asbestosis (BKV 4103)12237 (30.3)85 (69.7)1.9660.823–4.6980.128
    1/1 and 1/2 ILO6619(28.8)47 (71.2)2.2880.798–6.5640.124
    2/1, 2/2 and 2/3 ILO4615 (32.6)31 (67.4)1.450.524–4.0130.475
    3/2, 3/3 and 3/+ ILO93(33.3)6 (66.7)1.970.19–20.450.57
  Lung fibrosis of other aetiology5519 (34.5)36 (65.5)1.3130.579–2.9780.514
Malignant mesothelioma349 (26.5)25 (73.5)1.9180.675–5.4500.222
Lung cancer (LC)364129 (35.4)235 (64.6)1.0910.574–2.0740.79
  Asbestos induced LC (BKV 4104)4916 (32.7)33 (67.3)2.1120.754–5.9160.155
  LC of other aetiology315113 (35.9)202 (64.1)1.0020.521–1.9260.995

[i] Data adjusted for the pack years (PY), gender and age (years) were used to calculate the odds ratios (OR) for the IL-6 G-174C polymorphism in patients of the investigated groups compared to the healthy controls. OR analyses were performed for the more frequent genotypes (G-174G) vs. the genotypes carrying at least one of the less frequent (C) allele (G-174C or C-174C).

Clinical manifestation of IL-10 G-1082A polymorphisms

The frequency of the IL-10 (−1082) G-allele was 0.47 in the control and in the patient group. The OR analyses were performed for the genotype G-1082G vs. the genotypes carrying at least one A allele (G-1082A or A-1082A). Data was adjusted for PY, age (years) and gender. This analysis revealed that patients carrying at least one A allele of the IL-10 −1082 polymorphism were at higher risk for silicosis (ORsilicosis, 2.064; 95% CI, 0.78–5.49) but not for asbestosis (ORasbestosis, 0.986; 95% CI, 0.48–2.03) or fibrosis of other aetiology (ORfibrosis other aetiology, 0.903; 95% CI, 0.37–2.23). A higher risk was revealed for malignant mesothelioma (ORMM, 1.726; 95% CI, 0.54–5.51) (Table VI).

Table VI

Adjusted odds ratio of IL-10 G-1082A polymorphisms.

Table VI

Adjusted odds ratio of IL-10 G-1082A polymorphisms.

DiagnosisnGenotype, n(%)
Multivariate analysis
GGGA or AAOR95% CIp-value
Lung fibrosis605126 (20.8)479 (79.2)1.1440.586–2.2350.693
  Silicosis (BKV 4101)16128 (17.4)133 (82.6)2.0640.776–5.4920.147
  Asbestosis (BKV 4103)38984 (21.6)305 (78.4)0.9860.480–2.0270.97
  Lung asbestosis (BKV 4103)12224 (19.7)98 (80.3)0.9220.357–2.3810.867
    1/1 and 1/2 ILO6616 (24.2)50 (75.8)0.7610.260–2.2230.617
    2/1,2/2 and 2/3 ILO468 (17.4)38 (82.6)1.1330.342–3.7570.838
    3/2, 3/3 and 3/+ ILO90 (0.0)9 (100.0)---
  Lung fibrosis of other aetiology5514 (25.5)41 (74.5)0.9030.366–2.2270.825
Malignant mesothelioma346(17.6)27 (79.4)1.7260.541–5.5080.356
Lung cancer (LC)36484 (23.1)280 (76.9)1.1650.565–2.3990.679
  Asbestos induced LC (BKV 4104)4913 (26.5)36 (73.5)1.2390.389–3.9460.717
  LC of other aetiology31571 (22.5)244 (77.5)1.1670.56–2.4340.68

[i] Data adjusted for the pack years (PY), gender and age (years) were used to calculate the odds ratios (OR) for the IL-10 G-1082A polymorphism in patients of the investigated groups compared to the healthy controls. OR analyses were performed for the more frequent genotypes (G-1082G) vs. the genotypes carrying at least one of the less frequent (A) allele (G-1082A or A-1082A).

Clinical manifestation ofIL-1β C+3954T and IL-1β C-511T polymorphisms

The frequency of the less frequent IL-1β (+3954) T allele in the control group was 0.26 and in the patient group 0.25. The frequency of the less frequent IL-1β (−511) T allele was 0.31 in the control as well as in the patient group. The OR analyses were performed for the more frequent genotypes (C+3954C and C−511C) vs. the genotypes carrying at least one of the less frequent (T) allele (C+3954T or T+3954T and C−511T or T−511T). Data was adjusted for PY, age (years) and gender.

Patients carrying at least one less frequent (T) allele of the IL-1β −511 polymorphism showed decreased risk for fibrotic and malignant lung diseases (ORasbestosis, 0.946; 95% CI, 0.50–1.79; ORsilicosis, 0.67; 95% CI, 0.30–1.51 and ORLC, 0.597; 95% CI, 0.32–1.13) but not for malignant mesothelioma (ORMM, 1.28; 95% CI, 0.49–3.33). Rather an increasing risk was seen for severe lung asbestosis (2/1, 2/2 and 2/3 ILO: OR, 1.29; 95% CI, 0.46–3.62; 3/1, 3/2 and 3/+ ILO: OR, 3.583; 95% CI, 0.27–47.47) (Table VII).

Table VII

Adjusted odds ratio of IL-1β C-511T polymorphisms.

Table VII

Adjusted odds ratio of IL-1β C-511T polymorphisms.

DiagnosisnGenotype, n(%)
Multivariate analysis
CCCT or TTOR95% CIp-value
Lung fibrosis605281 (46.4)324 (53.6)0.8180.454–1.4720.502
  Silicosis (BKV 4101)16181 (50.3)80 (49.7)0.6690.297–1.5080.332
  Asbestosis (BKV 4103)389173 (44.5)216(55.5)0.9460.502–1.7860.865
  Lung asbestosis (BKV 4103)12253 (43.4)69 (56.6)0.8610.376–1.9710.723
    1/1 and 1/2 ILO6635 (53.0)31 (47.0)0.6940.268–1.80.453
    2/1, 2/2 and 2/3 ILO4615 (32.6)31 (67.4)1.2930.462–3.6150.624
    3/2, 3/3 and 3/+ ILO93 (33.3)6 (66.7)3.5830.271–47.470.333
  Lung fibrosis of other aetiology5527 (49.1)28 (50.9)0.8540.382–1.9110.701
Malignant mesothelioma3414(41.2)20 (58.8)1.280.491–3.3340.614
Lung cancer (LC)364185 (50.8)179 (49.2)0.5970.317–1.1250.11
  Asbestos induced LC (BKV 4104)4923 (46.9)26 (53.1)0.9750.357–2.6640.961
  LC of other aetiology315162 (51.4)153 (48.6)0.5340.279–1.0240.059

[i] Data adjusted for the pack years (PY), gender and age (years) were used to calculate the odds ratios (OR) for the IL-1β C-511T polymorphism in patients of the investigated groups compared to the healthy controls. OR analyses were performed for the more frequent genotypes (C-511C) vs. the genotypes carrying at least one of the less frequent (T) allele (T-511C or T-511T).

This analysis revealed that patients carrying at least one T allele of the IL-1β +3954 polymorphism were at higher risk for moderate lung asbestosis (1/1 and 1/2 ILO: OR, 1.79; 95% CI, 0.69–4.64) as well as for hyaline pleural plaques (OR, 1.44; 95% CI, 0.6–3.5). Additionally, a higher risk was seen in the asbestos-induced lung cancer patients (ORLC asbestos, 1.27; 95% CI, 0.47–3.47) rather than in lung cancer of other aetiology (ORLC other aetiology, 1.055; 95% CI, 0.55–2.01) (Table VIII). Significance could not be gained in the described results.

Table VIII

Adjusted odds ratio of IL-1β C+3954T polymorphisms.

Table VIII

Adjusted odds ratio of IL-1β C+3954T polymorphisms.

Genotype, n (%)
Multivariate analysis
DiagnosisnCCCT or TTOR95% CIp-value
Lung fibrosis605343 (56.7)262 (43.3)0.9150.508–1.6470.766
  Silicosis (BKV 4101)16182 (50.9)79 (49.1)1.1750.525–2.630.694
  Asbestosis (BKV 4103)389228 (58.6)161 (41.4)0.8360.443–1.5770.58
  Lung asbestosis (BKV 4103)12266 (54.1)56 (45.9)1.1130.489–2.5330.798
    1/1 and 1/2 ILO6629 (43.9)37 (56.1)1.7890.69–4.6410.232
    2/1. 2/2 and 2/3 ILO4632 (69.6)14 (30.4)0.5940.21–1.6810.326
    3/2. 3/3 and 3/+ ILO94 (44.4)5 (55.6)0.9730.087–10.920.982
  Lung fibrosis of other aetiology5533 (60.0)22 (40.0)0.8280.37–1.8570.648
Malignant mesothelioma3419 (55.9)15 (44.1)1.170.454–3.0120.746
Lung cancer (LC)364207 (56.9)157 (43.1)1.1080.588–2.0870.751
  Asbestos induced LC (BKV 4104)4927 (55.1)22 (44.9)1.2720.467–3.4660.638
  LC of other aetiology315180 (57.1)135 (42.9)1.0550.553–2.0130.871

[i] Data adjusted for the pack years (PY), gender and age (years) were used to calculate the odds ratios (OR) for the IL-1β C+3954T polymorphism in patients of the investigated groups compared to the healthy controls. OR analyses were performed for the more frequent genotypes (C+3954C) vs. the genotypes carrying at least one of the less frequent (T) allele (C+3954T or T+3954T).

Discussion

Pneumoconiosis, such as asbestosis or silicosis are occupational lung diseases caused by inhaled dust particles. Among others, cytokines such as TNF-α, TGF-β, IL-1β, IL-6 or IL-10 play an important role in the pathogenesis of pneumoconiosis (1,3033). Coal dust exposure stimulates inflammatory response leading to increased release of IL-1 (5). In previous studies we described an association of TNF-α (34) and TGF-β (35) polymorphisms with asbestos induced diseases. Since interleukins play an important role in inflammatory processes, genetic factors of these genes could also modify the susceptibility of asbestos or silica-related diseases.

Our results did not show any association with the IL-1β (+3954) or IL-1β (−511) polymorphism. Also Yucesoy et al (36) did not find any association of the IL-1β (+3954) polymorphism with silicosis. In contrast a higher risk of lung cancer (OR, 5.45; 95% CI, 2.75–4.42) was reported for T-allele carriers in the Japanese population (37).

Inflammatory cytokines TNF-α, IL-1 and IL-6 are released during inflammation. IL-6 then shows anti-inflammatory effects by inhibiting the secretion of TNF-α and IL-1. Therefore IL-6 is a pro- and anti-inflammatory cytokine (38). The −174C allele of IL-6 was associated with a lower basal expression, which persisted also after stimulation with LPS or IL-1. Significant lower plasma level of IL-6 in healthy subjects was associated with the −174C allele (22). This study did not detect any significant effect of the IL-6 (−174G/C) polymorphism in a cohort of 1180 subjects. A tendency for a higher risk of C-allele carriers for fibrotic lung diseases, malignant mesothelioma or asbestos-induced lung cancer was noted. A significant association of the GG homozygous genotype with an improved survival in sepsis has been previously described (39). In contrast, a protective effect of the IL-6 variant was found on the development and severity of coal workers’ pneumoconiosis in Turkey (40).

IL-10 as an anti-inflammatory cytokine inhibits the release of proinflammatory mediators, such as TNF-α, IL-1β and IL-6 (23). Genotypes carrying the IL-10 −1082A allele are associated with a lower IL-10 production (4143). Our study revealed, that patients carrying at least one A allele are at lower risk for asbestosis or fibrotic lung diseases of other aetiology, but at higher risk for malignant mesothelioma. Significant higher risk for chronic obstructive pulmonary disease (COPD) (OR, 1.66; 95% CI, 1.01–2.75; P=0.0046) and small-cell lung cancer (SCLC) (OR, 3.01; 95% CI, 1.21–7.48; P=0.0006) was detected in German −1082G-allele carriers (44). Higher ORs (OR, 5.26; 95% CI, 2.65–10.4; P<0.0001) were observed for non-small cell lung cancer (NSCLC) in Chinese patients carrying the IL-10 −1082G allele (45). A higher frequency of the IL-10 −1082G allele was reported in Chinese patients with cardia gastric cancer (46). Worth noting is the fact that the −174C allele of IL-6 and the −1082A allele of IL-10 have opposite effects regarding fibrotic lung diseases.

This study did not reveal sufficient evidence for an association of the investigated interleukin polymorphisms with asbestos or silica-induced diseases. Since the system of carcinogenesis/fibrogenesis is very complex, the changes caused by one SNP may not have enough impact to reveal significance. Therefore, it appears to be important and appropriate to undertake more studies with new methods, to analyse combination effects and the multifaceted interactions between genetic and environmental factors (47).

Abbreviations:

BKV

occupational disease regulation;

PAH

poly-cyclic aromatic hydrocarbons;

LC

lung cancer;

LPS

lipopolysaccharide;

OR

odds ratio;

CI

confidence interval;

PY

pack year;

MM

malignant mesothelioma

Acknowledgements

Some of the results are included in the thesis of J. Wübbeling.

References

1. 

DW KampAsbestos-induced lung diseases: an updateTransl Res153143152200910.1016/j.trsl.2009.01.00419304273

2. 

J SchneiderR ArhelgerG Hauser-HeidtWertigkeit der statischen Compliance-Messung bei Asbestfaserstaub-verursachten Erkrankungen der Lunge und der PleuraWissenschaftlicher Abschlußbericht1792006(In German).

3. 

CB ManningV VallyathanBT MossmanDiseases caused by asbestos: mechanisms of injury and disease developmentInt Immunopharmacol2191200200210.1016/S1567-5769(01)00172-211811924

4. 

C DostertV PetrilliR Van BruggenC SteeleBT MossmanJ TschoppInnate immune activation through Nalp3 inflammasome sensing of asbestos and silicaScience320674677200810.1126/science.115699518403674

5. 

I AtesB YucesoyA YucelSH SuzenY KarakasA KarakayaPossible effect of gene polymorphisms on the release of TNF alpha and IL1 cytokines in coal workers’ pneumoconiosisExp Toxicol Pathol63175179201120005085

6. 

A WeberP WasiliewM KrachtInterleukin-1 (IL-1) pathway (Review)Sci Signal3cm12010

7. 

A WeberP WasiliewM KrachtInterleukin-1beta (IL-1beta) processing pathway (Review)Sci Signal3cm2201020086236

8. 

E VoronovDS ShouvalY KrelinIL-1 is required for tumor invasiveness and angiogenesisProc Natl Acad Sci USA10026452650200310.1073/pnas.043793910012598651

9. 

Y KrelinE VoronovS DotanInterleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumorsCancer Res6710621071200710.1158/0008-5472.CAN-06-295617283139

10. 

DM ElarajDM WeinreichS VargheseThe role of interleukin 1 in growth and metastasis of human cancer xenograftsClin Cancer Res1210881096200610.1158/1078-0432.CCR-05-160316489061

11. 

K BhattacharyaE DoppP KakkarBiomarkers in risk assessment of asbestos exposureMutat Res579621200510.1016/j.mrfmmm.2005.02.02216112146

12. 

MI LusterPP SimeonovaAsbestos induces inflammatory cytokines in the lung through redox sensitive transcription factorsToxicol Lett102–103271275199810022265

13. 

R ZhaiG LiuX GeSerum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), and their soluble receptors in coal workers’ pneumoconiosisRespir Med96829834200212412984

14. 

FA HoussiauJP DevogelaerJ Van DammeCN de DeuxchaisnesJ Van SnickInterleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritidesArthitis Rheum31784788198810.1002/art.17803106143260102

15. 

PC TrevilattoRM Scarel-CaminagaRB de Brito JrAP de SouzaSR LinePolymorphism at position −174 of IL-6 gene is associated with susceptibility to chronic periodontitis in a Caucasian Brazilian populationJ Clin Periodontol304384422003

16. 

RM GrossmanJ KruegerD YourishInterleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytesProc Natl Acad Sci USA8663676371198910.1073/pnas.86.16.63672474833

17. 

J BidwellL KeenG GallagherCytokine gene polymorphism in human disease: on-line databasesGenes Immun1319199910.1038/sj.gene.6363645

18. 

J BidwellL KeenG GallagherCytokine gene polymorphism in human disease: on-line databases, supplement 1Genes Immun26170200110.1038/sj.gene.636373311393658

19. 

MV HollegaardJL BidwellCytokine gene polymorphism in human disease: on-line databases, Supplement 3Genes Immun7269276200610.1038/sj.gene.636430116642032

20. 

SK HallDG PerregauxCA GabelCorrelation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta proteinArthritis Rheum5019761983200410.1002/art.2031015188375

21. 

F PociotJ MolvigL WogensenH WorsaaeJ NerupA TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitroEur J Clin Invest22396402199210.1111/j.1365-2362.1992.tb01480.x1353022

22. 

D FishmanG FauldsR JefferyThe effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritisJ Clin Invest10213691376199810.1172/JCI26299769329

23. 

R SabatG GrutzK WarszawskaBiology of interleukin-10Cytokine Growth Factor Rev21331344201010.1016/j.cytogfr.2010.09.002

24. 

KW MooreR de Waal MalefytRL CoffmanA O’GarraInterleukin-10 and the interleukin-10 receptorAnnu Rev Immunol19683765200110.1146/annurev.immunol.19.1.68311244051

25. 

A SuarezP CastroR AlonsoL MozoC GutierrezInterindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphismsTransplantation75711717200310.1097/01.TP.0000055216.19866.9A

26. 

American Thoracic SocietyIdiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)Am J Respir Crit Care Med161646664200010.1164/ajrccm.161.2.ats3-00

27. 

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial PneumoniasThis joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001Am J Respir Crit Care Med165277304200210.1164/ajrccm.165.2.ats01

28. 

WD TravisTumours of the Lung, Pleura, Thymus and HeartIARC PressLyon9562004

29. 

KG HeringM JacobsenE Bosch-GaletkeFurther development of the International Pneumoconiosis Classification - from ILO 1980 to ILO 2000 and to ILO 2000/German Federal Republic versionPneumologie575765842003(In German).

30. 

BT MossmanA ChurgMechanisms in the pathogenesis of asbestosis and silicosisAm J Respir Crit Care Med15716661680199810.1164/ajrccm.157.5.97071419603153

31. 

P NymarkH WikmanT Hienonen-KempasS AnttilaMolecular and genetic changes in asbestos-related lung cancerCancer Lett265115200810.1016/j.canlet.2008.02.04318364247

32. 

J SanceauJ WijdenesM RevelJ WietzerbinIL-6 and IL-6 receptor modulation by IFN-gamma and tumor necrosis factor-alpha in human monocytic cell line (THP-1). Priming effect of IFN-gammaJ Immunol1472630263719911918983

33. 

F HuauxM ArrasA VinkJC RenauldD LisonSoluble tumor necrosis factor (TNF) receptors p55 and p75 and inter-leukin-10 downregulate TNF-alpha activity during the lung response to silica particles in NMRI miceAm J Respir Cell Mol Biol21137145199910.1165/ajrcmb.21.1.357010385602

34. 

S HelmigN AliahmadiJ SchneiderTumour necrosis factor-alpha gene polymorphisms in asbestos-induced diseasesBiomarkers15400409201010.3109/1354750X.2010.48136520486865

35. 

S HelmigA BelweJ SchneiderAssociation of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumorsJ Investig Med57655661200919349911

36. 

B YucesoyV VallyathanDP LandsittelP SimeonovaMI LusterCytokine polymorphisms in silicosis and other pneumoconiosesMol Cell Biochem234–235219224200212162437

37. 

C KiyoharaT HoriuchiK TakayamaY NakanishiIL1B rs1143634 polymorphism, cigarette smoking, alcohol use, and lung cancer risk in a Japanese populationJ Thorac Oncol5299304201010.1097/JTO.0b013e3181c8cae320035239

38. 

DA PapanicolaouRL WilderSC ManolagasGP ChrousosThe pathophysiologic roles of interleukin-6 in human diseaseAnn Intern Med128127137199810.7326/0003-4819-128-2-199801150-000099441573

39. 

B SchluterC RaufhakeM ErrenEffect of the interleukin-6 promoter polymorphism (−174 G/C) on the incidence and outcome of sepsisCrit Care Med3032372002

40. 

I AtesHS SuzenB YucesoyIO TekinA KarakayaAssociation of cytokine gene polymorphisms in CWP and its severity in Turkish coal workersAm J Ind Med51741747200810.1002/ajim.2063218702109

41. 

DM TurnerDM WilliamsD SankaranM LazarusPJ SinnottIV HutchinsonAn investigation of polymorphism in the interleukin-10 gene promoterEur J Immunogenet2418199710.1111/j.1365-2370.1997.tb00001.x9043871

42. 

AR TamburJW OrtegelZ Ben-AriRole of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipientsTransplantation7114751480200110.1097/00007890-200105270-0002011391238

43. 

C PerreyV PravicaPJ SinnottIV HutchinsonGenotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical reportTranspl Immunol6193197199810.1016/S0966-3274(98)80045-29848226

44. 

C SeifartA PlagensA DempfleTNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancerDis Markers21157165200510.1155/2005/70713116276011

45. 

CM ShihYL LeeHL ChiouThe involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancerLung Cancer50291297200510.1016/j.lungcan.2005.07.00716122836

46. 

Y ZhouW HuW ZhuangX WuInterleukin-10 −1082 promoter polymorphism and gastric cancer risk in a Chinese Han populationMol Cell Biochem34789932010

47. 

EK SilvermanLJ PalmerCase-control association studies for the genetics of complex respiratory diseasesAm J Respir Cell Mol Biol22645648200010.1165/ajrcmb.22.6.f19110837359

48. 

J ParkerRadiological criteria: the use of chest imaging techniques in asbestos-related diseasesProceedings of an International Expert Meeting on Asbestos, Asbestosis and Cancer, People and Work, Research ReportsFinnish Institute of Occupational HealthHelsinki28401997

49. 

P DeVuystGuidelines for attribution of lung cancer to asbestosProceedings of an International Expert Meeting on Asbestos, Asbestosis and Cancer, People and Work, Research ReportsFinnish Institute of Occupational HealthHelsinki92961997

Related Articles

Journal Cover

August 2012
Volume 30 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Helmig S, Grossmann M, Wübbeling J and Schneider J: Interleukin gene polymorphisms in pneumoconiosis. Int J Mol Med 30: 401-408, 2012
APA
Helmig, S., Grossmann, M., Wübbeling, J., & Schneider, J. (2012). Interleukin gene polymorphisms in pneumoconiosis. International Journal of Molecular Medicine, 30, 401-408. https://doi.org/10.3892/ijmm.2012.996
MLA
Helmig, S., Grossmann, M., Wübbeling, J., Schneider, J."Interleukin gene polymorphisms in pneumoconiosis". International Journal of Molecular Medicine 30.2 (2012): 401-408.
Chicago
Helmig, S., Grossmann, M., Wübbeling, J., Schneider, J."Interleukin gene polymorphisms in pneumoconiosis". International Journal of Molecular Medicine 30, no. 2 (2012): 401-408. https://doi.org/10.3892/ijmm.2012.996